Abstract: Combinations of an IDO1 inhibitor (e.g., a 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione compound), with an anti-PD1 antibody or anti-PD-L1 antibody, and an anti-4-1BB antibody, as selected anti-cancer or anti-viral agents are provided. Also provided are use of these combinations for the treatment and/or prevention of cancer and endometriosis.
Abstract: Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.
Type:
Grant
Filed:
March 23, 2018
Date of Patent:
September 3, 2019
Assignee:
ITEOS THERAPEUTICS
Inventors:
Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
Abstract: Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.
Type:
Grant
Filed:
October 21, 2016
Date of Patent:
April 24, 2018
Assignee:
ITEOS THERAPEUTICS
Inventors:
Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose
Abstract: The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula I as IDO1 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer and endometriosis. The invention also relates to a process for manufacturing compounds of Formula I.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
March 28, 2017
Assignee:
ITEOS THERAPEUTICS
Inventors:
Stefano Crosignani, Sandra Cauwenberghs, Gregory Driessens, Frederik Deroose